Orca Bio
Bringing Precision to Life
- Headquarters
- Menlo Park, California
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- orcabio.com
- Total Funding
- $692.0M
- Last Round
- $250.0M Series FDec 2025
About
Orca Bio is a late-stage biotechnology company developing high-precision allogeneic T-cell immunotherapies for the treatment of cancer and autoimmune diseases. Its lead program, Orca-T, is designed to harness regulatory T cells to deliver durable remission with fewer risks than conventional stem cell transplants. The company has received FDA Priority Review for its Biologics License Application and completed a $250M aggregate financing in preparation for potential commercialization.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account